GlassScriptPhysician profile
Kaveh Sharif
NPI 1366465825
$2,031.95
in general payments reported to CMS, 2019-2025
17 companies · $496 in 2025
The $496 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2021: $130 · 2022: $273 · 2023: $340 · 2024: $328 · 2025: $496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,124 · Education: $39.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,124.30 |
| Education | $39.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Outset Medical INC | $308.64 | 2023-2024 | |
| Opko Pharmaceuticals, LLC | $236.97 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $228.16 | 2019-2025 | Farxiga, Lokelma |
| Ardelyx, INC. | $200.03 | 2024-2025 | Ibsrela |
| Akebia Therapeutics INC | $186.38 | 2025 | Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $185.07 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $147.76 | 2022-2025 | |
| Amgen INC. | $98.35 | 2019-2022 | |
| Glaxosmithkline, LLC. | $70.02 | 2024 | Jesduvroq |
| Baxter Healthcare | $70.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $67.77 | 2019-2021 | |
| Novo Nordisk INC | $66.19 | 2021-2022 | |
| Lilly USA, LLC | $53.73 | 2022 | |
| Organogenesis INC. | $37.76 | 2023 | Puraply |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.73 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $20.44 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.95 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaveh Sharif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.